In patients with LVNC and HFrEF, the addition of SGLT2 inhibitor therapy to concomitant heart failure treatment appears to be associated with favorable clinical outcomes and may contribute to reverse remodeling of the failing myocardium in this patient population. The gene discussed is SLC5A2; the disease is heart failure.